LON:REDX

Redx Pharma Share Forecast, Price & News

GBX 56.75
+0.25 (+0.44 %)
(As of 07/29/2021 10:58 AM ET)
Add
Compare
Today's Range
53.35
58.60
50-Day Range
52.13
68.75
52-Week Range
20
95
Volume31,988 shs
Average Volume35,510 shs
Market Capitalization£155.43 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive REDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter.


Redx Pharma logo

About Redx Pharma

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.74 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Redx Pharma (LON:REDX) Frequently Asked Questions

What stocks does MarketBeat like better than Redx Pharma?

Wall Street analysts have given Redx Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Redx Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Redx Pharma's earnings last quarter?

Redx Pharma Plc (LON:REDX) announced its quarterly earnings data on Monday, November, 19th. The company reported ($7.00) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($6.50) by $0.50.
View Redx Pharma's earnings history
.

How has Redx Pharma's stock been impacted by Coronavirus (COVID-19)?

Redx Pharma's stock was trading at GBX 6.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REDX shares have increased by 773.1% and is now trading at GBX 56.75.
View which stocks have been most impacted by COVID-19
.

Who are Redx Pharma's key executives?

Redx Pharma's management team includes the following people:
  • Ms. Lisa Mary Whewell Anson, CEO & Exec. Director (Age 51, Pay $508.37k)
  • Dr. James Mead, Chief Operating Officer (Age 43, Pay $195.93k)
  • Mr. Peter J. Collum, Chief Financial Officer
  • Dr. Richard Armer, Chief Scientific Officer
  • Dr. Jane Robertson, Chief Medical Officer
  • Andrew Booth, Sec.

Who are some of Redx Pharma's key competitors?

What other stocks do shareholders of Redx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Redx Pharma investors own include (DGS.L) (DGS), OptiBiotix Health (OPTI), TLA Worldwide (TLA), Be Heard Group plc (BHRD.L) (BHRD), salesforce.com (CRM), (ECA), Carnival Co. & (CCL), Burberry Group (BRBY), boohoo group (BOO) and The Bank of New York Mellon (BK).

What is Redx Pharma's stock symbol?

Redx Pharma trades on the London Stock Exchange (LON) under the ticker symbol "REDX."

How do I buy shares of Redx Pharma?

Shares of REDX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Redx Pharma's stock price today?

One share of REDX stock can currently be purchased for approximately GBX 56.75.

How much money does Redx Pharma make?

Redx Pharma has a market capitalization of £155.43 million and generates £6.61 million in revenue each year.

How many employees does Redx Pharma have?

Redx Pharma employs 40 workers across the globe.

What is Redx Pharma's official website?

The official website for Redx Pharma is redxpharma.com.

Where are Redx Pharma's headquarters?

Redx Pharma is headquartered at Block 33, Mereside,, Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom.

How can I contact Redx Pharma?

Redx Pharma's mailing address is Block 33, Mereside,, Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom. The company can be reached via phone at +44-151-7064747.


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.